Immunonutrition in Ulcerative Colitis

Phase

N/A

Condition

Colic

Ulcerative Colitis

Inflammatory Bowel Disease

Treatment

N/A

Clinical Study ID

NCT03594708

UCS2018

Ages > 18
All Genders

Study Summary

This study tests the hypothesis that a supplement that combines a functional fiber, long chain omega-3 polyunsaturated fatty acids (PUFAs), vitamin D3, vitamin E, and zinc will reduce clinical symptoms, decrease pro-inflammatory cytokines in the blood and ergo decrease inflammation, promote beneficial microbial activity in the colon, and help recovery of the intestinal mucosa of ulcerative colitis (UC) patients compared with a placebo.

Eligibility Criteria

Inclusion

Inclusion Criteria:

patients with active ulcerative colitis (proof of diagnosis from gastroenterologist),over 18 years old, has over 50% gut remaining, fully connected bowels (no colostomy),currently on 5-aminosalicylates (ASA) drugs, not pregnant or lactating

Exclusion

Exclusion Criteria:

Study Design

April 30, 2018

December 31, 2018

Study Description

An anticipated 30 participants with newly diagnosed active ulcerative colitis will be recruited to participate in a randomized control trial, with 50% of the subjects distributed to the supplement (n=15) and the other 50% provided a placebo control (n=15). This is considered as a "proof of concept" study to determine if there is evidence that a multi-ingredient supplement (immunonutrition) will reduce UC disease severity.

Connect with a study center

GI Specialists Foundation
Memphis, Tennessee 38120
United States
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.